DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data from preclinical studies of three exatecan-based ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today shared new preclinical data for ...

Researchers from Heidelberg Pharma AG have presented a new antibody-drug conjugate (ADC) that shows promise for treating pancreatic ductal adenocarcinoma (PDAC). The ADC, called hRS7 ATAC, targets ...

Third, Enhertu’s cysteine-based conjugation process is able to achieve a high drug-to-antibody ratio of around 7 to 8. This is much higher than the DAR’s of older generations of ADCs ...

The poster is available on Innate Pharma’s website. IPH4502 is a differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion ...

Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...

its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual ...

PF-08052666 was designed to address the limitations of earlier anti-MSLN ADCs through a novel antibody, differentiated linker ...

The Cancer Pioneers” has just dropped, giving audiences a moving first look at the groundbreaking new documentary that ...

Shanghai-based biotech Shijian Bio has signed an exclusive option agreement with US firm ConjugateBio to license its EZWi-Fit ...